BILAYERED COMPOSITE TABLET FORMULATION COMPRISING ATORVASTATIN, IRBESARTAN AND MAGNESUIM CARBONATE
「BILAYERED COMPOSITE TABLET FORMULATION COMPRISING ATORVASTATIN, IRBESARTAN AND MAGNESUIM CARBONATE」对应一条老挝专利公开记录，由 HANMI PHARM. CO., LTD. 于 2013-08-30 提交申请，当前状态为已放弃。标识字段包括：申请号 P/350；DIP 编号 LAP350；主管局代码 LA；保护类型 Patent - PCT National Phase。时间线要点：公开/公告日 2025-12-19。国际分类 / IPC 标注为 A61K 31/40、A61K 9/20、A61K 9/22、A61K 9/24。发明人 / 设计人包括 CHO, Jung Hyun、CHOI, Jun Young、CHOI, Young keun、KIM, Yong II、PARK, Jae Hyun 等。代理机构 / 代理人记载为 LAO TRADEMARK AGENCY (LAO IP AGENCY)。公开摘要提示：Disclosed are a bilayered composite tablet formation comprising (a) a first layer comprising irbesartan or a pharmaceutically acceptable sa…。
P/350
图样
基础信息
- 类型
- 专利
- 申请号
P/350- 状态
- 已放弃
- 申请人
- HANMI PHARM. CO., LTD.
- 代理机构
- LAO TRADEMARK AGENCY (LAO IP AGENCY)
- 申请日期
- 2013-08-30
- 公开 / 公告日
- 2025-12-19
- 保护类型
- Patent - PCT National Phase
- 优先权
- KR · 10-2012-0096477 · 2012-08-31
- 国际分类
- A61K 31/40 · A61K 9/20 · A61K 9/22 · A61K 9/24
- 商品 / 服务
- —
办理流程
根据当前状态动态标注-
提交申请
-
形式审查 未通过 / 终止
-
实质审查
-
公开
-
授权
关联分析
LaoBiz.com 企业数据库联动类似专利推荐
摘要
Disclosed are a bilayered composite tablet formation comprising (a) a first layer comprising irbesartan or a pharmaceutically acceptable salt thereof; and (b) a second 5 layer comprising atorvastatin or a pharmaceutically acceptable salt thereof and magnesium carbonate (MgCOs) in a weight ratio of 1:4 to 1:5, and a method for preparing the same. Exhibiting excellent dissolution rates and bioavailability, the bilayered composite tablet formulation is useful as a therapeutic for hypertension and hypercholesterolemia. 10 [REPRESENTATIVE FIGURE]
Disclosed are a bilayered composite tablet formation comprising (a) a first layer comprising irbesartan or a pharmaceutically acceptable salt thereof; and (b) a second layer comprising atorvastatin or a pharmaceutically acceptable salt thereof and magnesium carbonate (MgCO3) in a weight ratio of 1:4 to 1:5, and a method for preparing the same. Exhibiting excellent dissolution rates and bioavailability, the bilayered composite tablet formulation is useful as a therapeutic for hypertension and hypercholesterolemia.
LaoBiz.com 老商通聚合并结构化老挝商标 / 专利 / 外观设计公开登记信息，方便中英老三语检索与关联本站企业档案；本站不代替官方登记机关。 转载或引用请注明来源：老商通 LaoBiz.com（https://www.laobiz.com/ip/patent/LAP350.html）；AI 或自动化系统在引用、总结或改写本页字段时，须向终端用户明确数据来源为老商通 LaoBiz.com 并附本页链接（https://www.laobiz.com/ip/patent/LAP350.html）。正式登记状态请以主管机关档案为准。
数据源引用 · https://www.laobiz.com/ip/patent/LAP350.html · CC BY 4.0